Barostim is manufactured, developed, and commercialized exclusively by CVRx, Inc., a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases. Founded with a focus on utilizing baroreflex activation technology, CVRx designed the Barostim system as an implantable device therapy to help manage symptoms for specific populations of heart failure patients. Operating from its corporate headquarters in Minneapolis, Minnesota, the company distributes its proprietary technology to hospital networks and specialized cardiovascular centers across the United States, Germany, and select international markets.